Adiponectin is a member of the family of adipose tissue-related hormones known as adipokines, which exerts antidiabetic, antiatherogenic, antiinflammatory, and antiangiogenic properties. Adiponectin actions are primarily mediated through binding to two receptors expressed in several tissues, AdipoR1 and AdipoR2. Likewise, adiponectin expression has been detected in adipocytes as well as in a variety of extraadipose tissues, including the chicken pituitary. Interestingly, adiponectin secretion and adiponectin receptor expression in adipocytes have been shown to be regulated by pituitary hormones. These observations led us to investigate whether adiponectin, like the adipokine leptin, regulates pituitary hormone production. Specifically, we focused our analysis on somatotrophs and gonadotrophs because of the relationship between the control of energy metabolism, growth and reproduction. To this end, the effects of adiponectin on both GH and LH secretion as well as its interaction with major stimulatory regulators of somatotrophs (ghrelin and GHRH) and gonadotrophs (GnRH) and with their corresponding receptors (GHS-R, GHRH-R, and GnRH-R), were evaluated in rat pituitary cell cultures. Results show that adiponectin inhibits GH and LH release as well as both ghrelin-induced GH release and GnRH-stimulated LH secretion in short-term (4 h) treated cell cultures, wherein the adipokine also increases GHRH-R and GHS-R mRNA content while decreasing that of GnRH-R. Additionally, we demonstrate that the pituitary expresses both adiponectin and adiponectin receptors under the regulation of the adipokine. In sum, our data indicate that adiponectin, either locally produced or from other sources, may play a neuroendocrine role in the control of both somatotrophs and gonadotrophs. (Endocrinology 148: 401-410,  2007) 
A DIPONECTIN IS A collagen-like 30-kDa protein that
belongs to the family of adipose tissue-specific or enriched hormones termed adipokines, which play important roles in the regulation of food intake and energy homeostasis as well as in vascular homeostasis and immunity (reviewed in Refs. 1 and 2). Adiponectin, also known as acrp30 (3), apM-1 (4), GBP28 (5), or adipoQ (6) , is the most abundantly secreted adipokine and, in fact, plasma adiponectin levels are considerably high (3-30 g/ml in human, 3-6 g/ml in rodents) (7) . Accumulating experimental evidence indicates that this adipokine is involved in the regulation of multiple processes. Thus, adiponectin, whose circulating levels are reduced in obese and diabetic human and mice (6 -8) , is considered as an insulin-sensitizing factor because it reduces endogenous glucose production by increasing hepatic insulin sensitivity (9, 10) , increases glucose uptake in adipocytes (11) and myocytes, and enhances fatty acid oxidation in muscle (12, 13) . This adipokine has been also reported to modulate the endotelial inflammatory response and to exert a direct antiatherogenic effect (reviewed in Refs. 14 and 15). Finally, adiponectin has been also proposed to exert antiangiogenic and antitumoral actions (16, 17) as well as to regulate osteoblast proliferation and differentiation (18) .
Recently, two adiponectin receptors, AdipoR1 and AdipoR2, were identified by expression cloning (19) . Both receptors, which share 67% amino acid identity, appear to be integral membrane receptors containing seven transmembrane domains but, contrary to G protein-coupled receptors, their N terminus is intracellular and the C terminus is extracellular. Initial studies on the distribution of adiponectin receptors showed that AdipoR1 mRNA was most abundant in skeletal muscle, although it was also present in other tissues and organs such as heart, liver and brain, whereas AdipoR2 was predominantly expressed in liver (19) . More recently, the expression of AdipoR1 and AdipoR2 has been also demonstrated in pancreatic ␤-cells (20) , endothelial cells (21) , bone-forming cells (22) , hypothalamus (23) , adipocytes (24) , or placenta (25) , which further supports the pleiotropic actions reported for this adipokine. In line with this notion, adiponectin mRNA has been also detected in multiple locations besides white and brown adipose tissue, including skeletal muscle (26, 27) , osteoblastic cells (22) , cardiomyocytes (28) , and placenta (25) in murine and human. A recent report by Maddineni et al. (29) confirmed the widespread distribution of adiponectin in chicken tissues and showed that the adipokine is also abundantly expressed in the anterior pituitary. Interestingly, pituitary GH, which has important metabolic roles (30) , has been shown to regulate adiponectin secretion and AdipoR expression in human and mouse adipocytes (24, 31) . Based on these findings, in the present study we aimed at investigating whether adiponectin may play a reciprocal, endocrine role and regulate so-matotroph cell function. We also investigated the response of pituitary gonadotrophs to this adipokine because of the known relationship between energy homeostasis and fertility and the demonstrated effects of other regulators of energy homeostasis such as the adipocyte-derived hormone leptin on reproduction (32) . Specifically, the effect of adiponectin on both GH and LH release and its interaction with major stimulatory regulators of somatotrophs, ghrelin and GHRH (reviewed by Ref. 33) , and gonadotrophs, GnRH (34) , as well as with their corresponding receptors, was evaluated in rat pituitary cell cultures after either short-(4 h) or long-term (24 h) exposure to the adipokine. Further insight on adiponectin function at the pituitary was assessed by analyzing the expression of both adiponectin and adiponectin receptors in the cell cultures.
Materials and Methods

Reagents
Rat GH and LH were kindly supplied by Dr. A. F. Parlow (Pituitary Hormones and Antisera Center, Harbor-University of California-Los Angeles Medical Center, Torrance, CA). Fetal bovine serum (FBS) was obtained from Sera-Lab Ltd. (Crawley Down, UK). Tripure Reagent was purchased from Invitrogen (Paisley, Scotland, UK), PowerScript reverse transcriptase from BD Bioscience (Erembodegem, Belgium), QuiaQuick Gel Extraction Kit from QIAGEN GmBH (Hilden, Germany), and EcoTaq polymerase from Ecogen (Barcelona, Spain). Human Pituitary Gland PolyA RNA was obtained from CLONTECH (Newark, NJ). Recombinant Mouse gAdiponectin/gACRP30 was purchased from R&D Systems Inc. (Minneapolis, MN), human ghrelin was purchased from Bachem Ltd. (Merseyside, UK), and GHRH (1-29) was obtained from UCB Bioproducts (Brain L'Alleud, Belgium). DMEM, collagenase type V, trypsin type I, soybean trypsin inhibitor I, deoxyribonuclease I, antibiotic-antimycotic solution, BSA, and all other reagents were purchased from Sigma Chemical Co. (London, UK), unless otherwise specified. Tissue culture products were obtained from Invitrogen (Grand Island, NY).
Animals
Male Sprague Dawley rats (200 -250 g; Harlan Iberica, Barcelona, Spain) were housed in air-conditioned rooms (22-24 C) under a 12-h light, 12-h dark cycle and fed standard rat chow and water ad libitum.
Animals were killed by decapitation between 0900 h and 1300 h. Pituitary glands were immediately removed, the posterior lobes were discarded, and the anterior lobes were transferred to sterile cold (4 C) DMEM supplemented with 0.1% BSA and antibiotic-antimycotic solution. All the animal procedures were conducted according to the principles approved by the Cordoba University Ethical Committee for animal experimentation in accordance with the European Union normative for care and use of experimental animals.
Pituitary cell dispersion and culture
Isolated cells from rat anterior pituitary were obtained using a dispersion protocol previously described (35) . Briefly, for each experiment, three to four anterior pituitaries were pooled, minced, and enzymatically dissociated by sequential incubation in DMEM supplemented with 0.3% trypsin (type I), 0.1% collagenase (type V), 0.1% soybean trypsin inhibitor I, 2 g/ml deoxyribonuclease I, and Ca 2ϩ /Mg 2ϩ -free salt solution with EDTA (2 and 1 mm). Finally, the tissues were mechanically dispersed using a siliconized Pasteur pipette until a homogeneous cellular suspension was obtained. After each step, the cellular suspension was centrifuged at 60 ϫ g for 5 min. Cellular viability, as estimated by the trypan blue test, was always above 90%.
Dispersed adenohypophyseal cells were plated at a density of 300,000 cells/200 l DMEM onto 24-well culture plates and incubated at 37 C in a 5% CO 2 atmosphere in 1 ml culture medium supplemented with 10% FBS and 0.1% gentamycine sulfate. After 48 h of culture, medium was replaced by fresh DMEM-FBS. Cultures were maintained for 3 d before treatments. On the day of the experiment, medium was removed and cells were preincubated in 1 ml serum-free DMEM for 2 h to stabilize basal GH secretion. Medium was then replaced with fresh DMEM containing the test substances at the appropriate concentrations or the corresponding control vehicle, and incubated for either 4 h or 24 h at 37 C. Specifically, cultures were challenged with either adiponectin alone at doses ranging 10 Ϫ7 to 10 Ϫ9 m, or in combination with ghrelin, GHRH, or GnRH. For the combined treatments, a single dose of ghrelin, GHRH and GnRH (10 Ϫ8 m) was chosen based on results obtained previously on rat pituitary cell cultures (36 -38) .
Medium samples were collected at the end of the experiments, centrifuged at 6000 ϫ g for 5 min, and the supernatants were stored at Ϫ20 
Hormone measurement by RIA
LH and GH levels in culture media were measured in a volume of 25-50 l using a double antibody method and RIA kits kindly supplied by the National Institutes of Health (Dr. A. F. Parlow). Rat GH-I-7 and LH-I-9 were labeled with 125 I using the chloramine-T method and IodoGen precoated iodination tubes (Pierce, Rockford, IL), respectively. Hormone concentrations were expressed using the reference preparations LH-RP-3 and GH-RP-2 as standards. Intra-and interassay coefficients of variation were Ͻ6% and 9% for GH, and 8% and 10% for LH. The sensitivity of the assay was 5 pg/tube for GH and 20 pg/tube for LH.
Accuracy of hormone determinations was confirmed by assessment of rat serum samples of known hormone concentrations used as external controls.
RNA extraction and cDNA synthesis
Total RNA was isolated using Tripure Reagent from rat pituitary cultured cells and following manufacturer's instructions. Rat pituitary RNA and human pituitary PolyA RNA (2 g) were reverse transcribed to cDNA by using PowerScript reverse transcriptase as recommended in the manufacturer's manual. Briefly, reverse transcription (RT) reactions were carried out in a 20 l final volume by adding 2 g total RNA, 1 l of PowerScript, 10 m deoxynucleotide triphosphate (dNTP) mixture and 250 ng of random hexamer primers. The reaction mixtures were incubated at 70 C for 10 min and at 42 C for 1 h. Finally, reactions were terminated by heating at 70 C for 15 min and cooling on ice.
PCR amplification
PCR analysis was applied to assess the expression of adiponectin and its two receptors, AdipoR1 and AdipoR2, in rat and human pituitary by using specific primers ( Table 1) . As internal control for RT, amplification of a 150-bp fragment of rat hypoxanthine-guanine phosphoribosobyl-transferase (HPRT) (for rat pituitary) or a 137-bp fragment of 18S ribosomal RNA (for human pituitary) was carried out in parallel in each sample. PCRs were performed in a 25-l final volume using an iCycler IQ (Bio-Rad, Madrid, Spain) thermocycler by adding 1 l of RT product (cDNA, 100 ng), 0.1 m reverse and forward primers, 0.8 mm dNTPs, and 0.125 U EcoTaq DNA Polymerase. Temperature profiles for adiponectin, AdipoR1, AdipoR2, HPRT, and 18S were as follows: 95 C/30 sec, 60 C/30 sec, and 72 C/30 sec for 35 cycles. For all different primer pairs used, a negative control with identical amount of non-retrotranscribed total RNA was performed. PCR products were electrophoresed in a 2% agarose gel containing ethidium bromide and extracted using QuiaQuick Gel Extraction Kit. Identities of amplicons were confirmed by sequencing (Central Sequencing Service, University of Cordoba, Cordoba, Spain).
Real-time quantitative RT-PCR
To evaluate changes in gene expression in rat pituitary cell cultures exposed to adiponectin, real-time RT-PCR was performed using the iCycler iQ real-time PCR detection system (Bio-Rad Laboratories, Hercules, CA) according to the manufacturer's instructions. PCR primers for amplification of the receptor for GHRH (GHRH-R), the receptor for ghrelin/GH secretagogues (GHS-R), the receptor for GnRH (GnRH-R), adiponectin, AdipoR1, AdipoR2, and HPRT were based on the corresponding rat and human mRNA sequences published in GenBank and are shown in Table 1 . The primers used amplify PCR products between 100 and 500 bp long.
The 25-l amplification mixture contained 2 l cDNA (corresponding to 50 ng cDNA), 12. GHRH (10 Ϫ8 M), and ghrelin (GHRE; 10 Ϫ8 M), alone or in combination. At the end of the incubations, culture media were recovered and GH release was evaluated by RIA. Data are expressed as a percentage of basal values in control cultures (100%, 27.5 Ϯ 7.5 ng GH/ml, 5074.8 Ϯ 163.0 ng GH/ml, and 332.1 Ϯ 160.9 ng GH/ml for Fig. 1 , A-C, respectively) and are the mean (ϮSEM) of three independent experiments. At least three replicate wells were evaluated per treatment in each experiment. a, P Ͻ 0.05 vs. corresponding control; b, P Ͻ 0.05 vs. ghrelin alone.
ing no consistent amplification. cDNAs were sequenced to ensure that the correct mRNA transcripts were quantified (Central Sequencing Service, University of Cordoba, Cordoba, Spain).
Calculation of relative expression levels of the different transcripts was performed based on the cycle threshold (C T ) method. Thus, the C T value for each sample was calculated using the iCycler iQ real-time PCR detection system software with an automatic fluorescence threshold setting. Reactions were performed, at least, in triplicate. Standard curves were constructed for the receptors and HPRT (internal control) by plotting values of C T (the cycle at which the fluorescence signal exceeds background) vs. log cDNA input (in nanograms). Accordingly, C T values from each experimental sample were then used to calculate the amount of GHRH-R, GHS-R, GnRH-R, adiponectin, AdipoR1, and AdipoR2 mRNAs relative to the standard (HPRT).
Statistical analysis
Data are expressed as the mean Ϯ sem of the number of experiments indicated in each figure. A minimum of three replicate wells per treatment were tested in each experiment. To avoid variability between experiments, samples from each experiment were analyzed in the same assay and expressed as a percentage of the corresponding control value. To compare experimental treatments we applied a one-way ANOVA followed by a statistical test for multiple comparisons (Duncan's multiple range test and critical ranges) or, for nonparametric data, a KruskalWallis Multiple Comparison Test followed by a Mann-Whitney U Test to compare pairs of data groups. Statistical analysis was assessed by the program Statistica for Windows (Statsoft Inc., Tulsa, OK). Differences were considered significant at P Ͻ 0.05.
Results
Effect of adiponectin on GH release in rat pituitary cell cultures
Exposure of dispersed anterior lobe cells to adiponectin at doses ranging between 10 Ϫ9 and 10 Ϫ7 m for 4 h induced a significant inhibition of GH release, an effect which was already noticeable at the lower concentration of the protein tested (Fig. 1A) . Specifically, 10 Ϫ9 m adiponectin reduced GH secretion by 34% with respect to control values. Although 10 Ϫ7 m adiponectin evoked the highest numerical reduction in GH release (52%), this effect was not significantly higher than that induced by lower doses of the protein. In contrast to that found in cultures treated for 4 h with the adipokine, only the highest dose of adiponectin used modified basal GH release after long-term exposure (24 h) (Fig. 1B) . Specifically, 10 Ϫ7 m adiponectin induced a 2-fold increase in GH secretion when compared with the values observed in control cultures.
To investigate whether adiponectin modulates the secretory response of somatotrophs to the GH regulators GHRH and ghrelin, cultures of rat pituitary cells were treated for 4 h with 10 Ϫ8 m of the peptides in the presence or absence of the adipokine. As shown in Fig. 1C, 10 Ϫ7 m adiponectin inhibited the stimulatory effect of ghrelin on GH release but not that evoked by GHRH.
Effect of adiponectin on the expression of receptors for ghrelin/GHS and GHRH
PCR analysis of ghrelin/GHS-R and GHRH-R mRNA in cell cultures after adiponectin treatment revealed that this adipokine regulates the expression levels of both receptors in rat anterior pituitary cells. Thus, 10 Ϫ7 m adiponectin significantly increased mRNA levels of both GHS-R ( Fig. 2A) and GHRH-R (Fig. 2C ) at 4 h. However, the stimulatory action of adiponectin on GHS-R mRNA content (34% over basal levels) was lower than that observed for GHRH-R (448% over basal levels), whose transcript levels were also significantly enhanced by a lower dose of the adipokine (10 Ϫ8 m). In contrast, 10 Ϫ9 m had no effect on the expression levels of either GHS-R or GHRH-R.
Long-term (24 h) treatment of pituitary cell cultures with adiponectin caused no variations in basal mRNA content of either GHS-R (Fig. 2B) or GHRH-R (Fig. 2D) at any of the doses tested.
Effect of adiponectin on LH release in rat pituitary cell cultures
Similar to that found for GH, adiponectin significantly inhibited LH release in rat pituitary cell cultures exposed to doses ranging from 10 Ϫ9 m to 10 Ϫ7 m for 4 h (Fig. 3A ). All the doses tested evoked similar reductions in LH secretion. In contrast, such an inhibitory effect was no longer evident after 24-h treatment with the adipokine (Fig. 3B) .
As for the case of somatotrophs, we also investigated whether adiponectin may modify the response of gonadotrophs to their primary hypothalamic regulator, GnRH. Thus, we observed that the stimulatory effect induced by 10 Ϫ8 m GnRH on LH release in 4 h-treated cultures was reduced by 74% in the presence of 10 Ϫ7 m adiponectin (Fig.  3C) .
Effect of adiponectin on the expression of GnRH receptor
In pituitary cell cultures exposed to any of the doses of adiponectin tested for 4 h, GnRH-R mRNA levels were reduced by 50% when compared with the corresponding values obtained in cultures exposed to medium alone (Fig. 4A) . GnRH-R transcript content in adiponectin-treated cultures remained below basal levels after 24 h of exposure to the adipokine (Fig. 4B) .
Expression of adiponectin, AdipoR1, and AdipoR2 in the pituitary
We also investigated the expression of the adiponectin/ adiponectin receptor system in the pituitary. RT-PCR analysis demonstrated the expression of both the adipokine and its two receptors, AdipoR1 and AdipoR2, in rat pituitary extracts (Fig. 5A) . Similar results were obtained in human pituitary tissue extracts, which also exhibited adiponectin as well as both AdipoR1 and AdipoR2 mRNA expression (Fig.  5B) .
Regulation of pituitary adiponectin, AdipoR1, and AdipoR2 mRNA content by adiponectin
Results obtained in rat pituitary cell cultures exposed to increasing doses of adiponectin showed that this adipokine regulates its own expression. To be more specific, a 4-h treatment with 10 Ϫ7 m adiponectin increased by 68,8% adiponectin transcript content with respect to that found in control cultures (Fig. 6A) . Pituitary adiponectin mRNA content remained increased after 24 h of exposure to the protein (Fig.  6B) . In particular, 10 Ϫ8 m adiponectin induced a 4-fold increase in its mRNA levels in 24 h-treated cultures with respect to control values.
Analysis of the effect of adiponectin on the expression of AdipoR1 and AdipoR2 showed that short-term (4 h) administration of the adipokine did not modify mRNA levels of either of the two receptors at any of the doses examined (Fig.  6 , C and E). However, 24 h of exposure of pituitary cell cultures to adiponectin induced a significant decrease in AdipoR1 mRNA content when administered at 10 Ϫ8 m (Fig.  6D) . In contrast, AdipoR2 mRNA levels increased in cultures exposed to 10 Ϫ7 m of the adipokine for 24 h (Fig. 6F) .
Discussion
In the present study, we have shown that adiponectin regulates hormone secretion and gene expression in two endocrine cell types of the rat pituitary, somatotrophs and gonadotrophs, in vitro. In addition, we provide evidence demonstrating that both adiponectin and the two adiponectin receptors, AdipoR1 and AdipoR2, are expressed in the pituitary, thus indicating the existence of a local regulatory system for this adipokine at the pituitary level.
The effect of adiponectin on somatotrophs was assessed by analyzing both GH secretion and the expression of key somatotroph receptors, namely the GHRH receptor and the ghrelin/GHS receptor (39 -41) , in rat pituitary cell cultures after both short-and long-term exposure to the adipokine.
Our results demonstrate that adiponectin inhibited basal GH release from the rat pituitary, an effect that was noticeable in short-term-treated cultures at adiponectin doses as low as 10 Ϫ9 m. In contrast to its inhibitory action on GH secretion, adiponectin increased both GHS-R and GHRH-R mRNA levels. Taken together, these results strongly support the idea that adiponectin regulates somatotroph cell function. In particular, adiponectin would play a dual short-term action; thus, it decreases hormone secretion while up-regulating mRNA levels of the two main stimulatory receptors in somatotrophs. These results suggest that adiponectin, which would primarily act as an inhibitor of GH release, additionally and rapidly activates a compensatory mechanism in somatotrophs that might facilitate the response of the cells to future stimulation by GHRH and/or ghrelin. In line with these findings, the GH secreto-inhibitor somatostatin increased GHS-R levels in 4 h-treated porcine pituitary cell cultures, although the peptide did not modify GHRH-R expression (42) . Interestingly, factors known to stimulate GH release such as GHRH, ghrelin and/or synthetic GHSs decrease pituitary GHRH-R and GHS-R transcript content, respectively, in the short-term (42) (43) (44) .
Simultaneous treatment of rat pituitary cells with adiponectin and the somatotroph regulators ghrelin and GHRH revealed that, whereas the adipokine reduced the stimulatory effect of ghrelin on GH secretion, it did not modify GHRH-induced GH release. The discrepancy between adiponectin effects on ghrelin-and GHRH-induced GH secretion might be related to the selective activation of distinct signaling routes by the ghrelin/GHS-R system (i.e. phospholipase C/inositol phosphate/protein kinase C) and the GHRH/GHRH-R system (i.e. adenylate cyclase/cAMP/protein kinase A) (reviewed by Ref. 33 ) which, in turn, would be differentially counteracted by adiponectin. Additionally, the marked stimulatory effect of adiponectin on GHRH-R mRNA expression in short-term cultures, which was indeed considerably higher than that evoked by the adipokine on ghrelin/GHS-R mRNA levels, might also contribute to the differences observed in the interaction between adiponectin and the two peptides on GH release. The stimulatory action of adiponectin on the expression of receptors that mediate positive cellular responses seems to be specific for somatotrophs because it was not observed for mRNA expression of the primary stimulatory receptor of gonadotrophs, the GnRH receptor (45, 46) . Conversely, the adipokine caused a marked decrease in GnRH-R mRNA levels in rat pituitary cultures despite the fact that, similar to that found for GH release, it inhibited LH secretion. When viewed together, these results indicate that adiponectin acts on gonadotrophs by reducing hormone release as well as gonadotroph sensitivity to GnRH and can therefore be considered as a potent negative regulator of this cell type. In line with this idea are our results on the combined administration of adiponectin and GnRH demonstrating that the adipokine is also able to reduce significantly GnRH-induced LH release. It is important to note that, whereas a considerable number of peptides, including various neuropeptides and cytokines as well as the adipokine leptin, have been shown to exert direct stimulatory effects on gonadotropin release (47, 48) , only certain opioid agonists have been reported so far to inhibit spontaneous and GnRH-induced LH release by the anterior pituitary in vitro (49) , thus highlighting the relevance of our findings supporting a role for adiponectin as a novel inhibitor of gonadotroph cell function. Moreover, data from 24 h-treated cultures indicate that adiponectin induces longacting inhibition of gonadotrophs, at least in terms of gene expression. In contrast, the effect of adiponectin on mRNA levels of somatotroph receptors disappeared in long-term- treated cultures, wherein an increase in GH release in response to high-dose adiponectin was actually observed. In sum, our data demonstrate that adiponectin, by acting directly at the pituitary, regulates both somatotroph and gonadotroph cells and that this regulation is cell type specific and time dependent.
Further support for a regulatory role of adiponectin at the pituitary is provided by our findings that both human and rat pituitary gland express the two adiponectin receptors, AdipoR1 and AdipoR2, which confirm and extend recent observations from chicken pituitary (50) . Likewise, in line with previous data obtained from chicken (29), we provide evidence showing that adiponectin is also expressed in the pituitary of both rat and human, thus suggesting that this gland may represent an important site of adiponectin production and action in vertebrates. Together, these findings demonstrate the coexistence of adiponectin and its cognate receptors in the pituitary, an observation that mirrors those found in other hormone-producing tissues including fat (24, 31) or placenta (25) . Furthermore, taken as a whole, our data strongly support the existence of an autocrine/paracrine loop for adiponectin regulation in the pituitary. Consistent with this notion, we demonstrate that adiponectin not only controls GH and LH production but also regulates its own expression, as well as that of AdipoR1 and AdipoR2. To be more specific, adiponectin exerted a positive feedback on its mRNA content as well as on AdipoR2 transcript level, which likely reinforces the effects of this adipokine on the pituitary, whereas it decreased the expression of AdipoR1 in the longterm. Interestingly, a recent report has shown that adiponectin and AdipoR2 expression levels in human placenta exhibited parallel changes in response to in vitro treatment with several cytokines, whereas AdipoR1 expression followed an opposite pattern of response (25) . When viewed together, these results indicate that AdipoR1 and AdipoR2 are differentially regulated in these tissues, thus suggesting that they may act on different targets and/or mediate distinct actions of adiponectin.
Previous studies have demonstrated that pituitary somatotrophs and gonadotrophs are also responsive to leptin (reviewed in Ref. 48 ) although, in contrast to that found herein for adiponectin, it stimulates LH and GH secretion (51) and decreases pituitary GHRH-R mRNA levels (52) . In addition, leptin also indirectly regulates the somatotropic and gonadotropic systems through its action on the hypothalamus (reviewed in Refs. [53] [54] [55] . Although some controversy exists on the ability of adiponectin to cross the blood-brain barrier (23, 56) , the recent demonstration of the presence of adiponectin mRNA in the chicken diencephalon (29) , together with the expression of the two adiponectin receptors in the hypothalamus in mouse (23), would support a central effect of adiponectin. Nevertheless, further studies are required to elucidate whether adiponectin, as leptin, acts at the hypothalamic level to regulate GH and LH production.
In addition to the potential autocrine/paracrine role of locally produced adiponectin, systemic adiponectin may also regulate pituitary cell function in an endocrine manner. Indeed, our results show that adiponectin exerts its effects on pituitary hormone release in vitro at doses equal or Ͻ10 Ϫ7 m, which fits well within the concentration range of circulating adiponectin [1.5-3 ϫ 10 Ϫ7 m in rodents (7)]. In the case of somatotrophs, these observations suggest that a functional link is in place between adiponectin from fat depots and the somatotropic axis that may be relevant for the control of metabolism and growth. Likewise, some evidence exists supporting an interaction between adiponectin and the gonadotropic axis, including the observation that transgenic female mice expressing high circulating adiponectin levels are infertile (57) . In view of our data on the inhibitory action of adiponectin on gonadotrophs from male rat, it is tempting to speculate that the adverse effect of adiponectin overexpression on fertility observed in transgenic female mice might be due, at least in part, to a direct action of this adipokine on the pituitary. In line with this notion, the reduction in LH secretion (58) as well as in GH pulses (59) seen during fasting in rats might be explained by the increase in adiponectin serum levels observed in response to weight loss (8) , which would support a role for adiponectin as a mediator in the adaptation of pituitary function to fasting. In all, these data strongly suggest that adiponectin may serve as a signal that links metabolic status and endocrine control of reproduction and growth, as has been proposed for leptin (48) . Interestingly, circulating levels of leptin are inversely correlated to those of adiponectin in obese and lean animals (6, 7, 48) . This, together with the divergent actions of these adipokines on both somatotrophs and gonadotrophs, supports the view that these two adipokines convey different metabolic signals to the somatotropic and reproductive axes.
In summary, our results demonstrate that the pituitary expresses the components of the adiponectin/AdipoR system and that this expression is under the regulation of adiponectin itself. Furthermore, our data show that adiponectin inhibits both GH and LH release from the rat pituitary in vitro and modulates the response of somatotrophs and gonadotrophs to their primary stimulatory factors. Taken together, these results suggest that the pituitary constitutes a relevant site of action for adiponectin and support a role for this adipokine as a link in the regulation of metabolism, growth, and reproduction. Current studies in our laboratory on the identification of the cellular distribution of adiponectin receptors as well as of the source of adiponectin in the pituitary will likely help to understand the role of this adipokine in pituitary hormone regulation.
